| Literature DB >> 33092519 |
Mikhail V Shaposhnikov1,2, Nadezhda V Zemskaya2, Lyubov А Koval2, Natalya R Minnikhanova2, Olga I Kechko1, Vladimir A Mitkevich1, Alexander A Makarov1, Alexey А Moskalev3,4.
Abstract
BACKGROUND: Beta-amyloid peptide (Aβ) is the key protein in the pathogenesis of Alzheimer's disease, the most common age-related neurodegenerative disorder in humans. Aβ peptide induced pathological phenotypes in different model organisms include neurodegeneration and lifespan decrease. However, recent experimental evidence suggests that Aβ may utilize oligomerization and fibrillization to function as an antimicrobial peptide (AMP), and protect the host from infections. We used the power of Drosophila model to study mechanisms underlying a dual role for Aβ peptides.Entities:
Keywords: Aging; Amyloid-β peptides; Antimicrobial peptides; Drosophila melanogaster; Lifespan; Peroxiredoxin 5; Transcription factor FOXO
Mesh:
Substances:
Year: 2020 PMID: 33092519 PMCID: PMC7583308 DOI: 10.1186/s12863-020-00866-y
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Influence of Aβ peptides on median and maximum lifespan
| Variant | Sex | M (days) | dM (%) | FET (p) | 90% (days) | d90% (%) | WAT (p) | n |
|---|---|---|---|---|---|---|---|---|
| control | male | 56 | 66 | 275 | ||||
| Aβ42 | male | 56 | 0.0 | 0.4706 | 66 | 0.0 | 0.464 | 282 |
| isoD7-Aβ42 | male | 56 | 0.0 | 0.3906 | 64 | −3.0 | 0.053 | 282 |
| pS8-Aβ42 | male | 56 | 0.0 | 0.7325 | 64 | −3.0 | 0.293 | 278 |
| control | female | 67 | 74 | 294 | ||||
| Aβ42 | female | 64 | −4.5* | 0.0024 | 71 | −4.1 | 0.078 | 301 |
| isoD7-Aβ42 | female | 64 | −4.5 | 0.1668 | 74 | 0.0 | 0.554 | 258 |
| pS8-Aβ42 | female | 64 | −4.5* | 0.0022 | 74 | 0.0 | 0.995 | 262 |
M (days) - median lifespan; 90% (days) - age of 90% mortality (maximum lifespan); dM (%), d90% (%), − differences between median and maximum (age of 90% mortality) lifespan of control and experimental flies, respectively; n - number of flies; *p < 0.01, FET - Fisher’s exact test (median lifespan comparison), WAT - Boschloo’s (Wang-Allison) test (maximum lifespan comparison)
Fig. 1Effects of the amyloid-β peptides on lifespan (a, b), locomotor activity (c, d), and gene expression (e, f) in males (a, c, e) and females (b, d, f). *р < 0.05, **р < 0.01, ***p < 0.001, log-rank test (survival data comparison), Fisher’s exact test (median lifespan (dM) comparison), and Student’s t-test (comparison of locomotor activity and gene expression). The error bars show standard errors. For lifespan analysis the total number of flies (n) used in two replicates (5 vials in each) is indicated in parentheses. For locomotor activity and qRT-PCR analyses the number of flies (n) used in each replication of experiment multiplied by the number of replicates are indicated in parentheses. For detailed description see Materials and methods
Cox proportional hazards analysis. Proportional hazard modeled for Aβ peptide (treatment versus control) and vials (10 vials in each experimental variant) as covariates with partial likelihood estimation
| Variant | Risk factor | HR | SE | |
|---|---|---|---|---|
| Aβ42 males | vial | 0.015 | ||
| Aβ peptide | 0.924 | 0.085 | 0.355 | |
| Aβ42 females | vial | 0.971 | 0.029 | 0.313 |
| Aβ peptide | 0.083 | |||
| isoD7-Aβ42 males | vial | 0.015 | ||
| Aβ peptide | 1.008 | 0.043 | 0.848 | |
| isoD7-Aβ42 females | vial | 0.971 | 0.029 | 0.313 |
| Aβ peptide | 0.993 | 0.043 | 0.861 | |
| pS8-Aβ42 males | vial | 1.005 | 0.004 | 0.159 |
| Aβ peptide | 0.961 | 0.029 | 0.179 | |
| pS8-Aβ42 females | vial | 0.971 | 0.029 | 0.313 |
| Aβ peptide | 1.013 | 0.028 | 0.643 |
Hazard ratios (HR) indicates fold change of the hazard (risk of death) for variants with higher values of that variable. The risk factor Aβ peptide is encoded by 1 (untreated control) and 2 (treated with Aβ peptide). The vials are numbered from 1 to 10 in each experimental variant as pseudoreplicates. HR greater than one indicates increased risk of death. Significant estimates in bold. SE - standard error
Analysis of differences in locomotor activity factored by age and conditions using two-way ANOVA
| Variant | Source of variation | SS | DF | MS | F | F-crit | |
|---|---|---|---|---|---|---|---|
| males | |||||||
| pS8-Aβ42 | Condition | 4231.89 | 1 | 4231.89 | 0.918 | 0.344 | 7.396 |
| 3,031,998.79 | 5 | 606,399.76 | 131.572 | 3.574 | |||
| Interaction | 25,648.17 | 5 | 5129.63 | 1.113 | 0.371 | 3.574 | |
| Within (errors) | 165,919.81 | 36 | 4608.88 | ||||
| Total | 3,227,798.65 | 47 | |||||
| Aβ42 | Condition | 3615.74 | 1 | 3615.74 | 0.623 | 0.435 | 7.396 |
| 3,237,235.33 | 5 | 647,447.07 | 111.585 | 3.574 | |||
| Interaction | 34,015.75 | 5 | 6803.15 | 1.172 | 0.342 | 3.574 | |
| Within (errors) | 208,882.47 | 36 | 5802.29 | ||||
| Total | 3,483,749.29 | 47 | |||||
| isoD7-Aβ42 | 46,787.54 | 1 | 46,787.54 | 4.357 | 7.396 | ||
| 4,055,146.09 | 5 | 811,029.22 | 75.526 | 3.574 | |||
| Interaction | 17,717.56 | 5 | 3543.51 | 0.33 | 0.892 | 3.574 | |
| Within (errors) | 386,580.72 | 36 | 10,738.35 | ||||
| Total | 4,506,231.91 | 47 | |||||
| females | |||||||
| pS8-Aβ42 | Condition | 148.05 | 1 | 148.05 | 0.32 | 0.575 | 7.396 |
| 357,497.08 | 5 | 71,499.42 | 154.507 | 3.574 | |||
| Interaction | 1593.83 | 5 | 318.77 | 0.689 | 0.635 | 3.574 | |
| Within (errors) | 16,659.28 | 36 | 462.76 | ||||
| Total | 375,898.24 | 47 | |||||
| Aβ42 | 3605.33 | 1 | 3605.33 | 6.954 | 7.396 | ||
| 383,645 | 5 | 76,729 | 147.986 | 3.574 | |||
| Interaction | 3418.1 | 5 | 683.62 | 1.318 | 0.278 | 3.574 | |
| Within (errors) | 18,665.55 | 36 | 518.49 | ||||
| Total | 409,333.98 | 47 | |||||
| isoD7-Aβ42 | 3918.66 | 1 | 3918.66 | 4.696 | 7.396 | ||
| 338,379.79 | 5 | 67,675.96 | 81.098 | 3.574 | |||
| Interaction | 5280.92 | 5 | 1056.18 | 1.266 | 0.299 | 3.574 | |
| Within (errors) | 30,041.99 | 36 | 834.5 | ||||
| Total | 377,621.36 | 47 | |||||
SS Sum-of-squares, DF degrees of freedom, MS mean squares. Results of F-tests: F-value (F), P-value, F-critical value (F-crit). Significant estimates in bold
List of primers used for real-time qRT-PCR analysis of gene expression
| Gene | Forward | Reverse |
|---|---|---|
| 5′-ggccaactgaacgctgatct-3’ | 5′-aagccgggcatgaagaagtg-3’ | |
| 5′-agggcaagaagtagctggtttgc-3’ | 5′-gctgctactactgcgtgttgttg-3’ | |
| 5′-acaggcccaagatcgtgaag-3’ | 5′-tgttgtcgatacccttgggc-3’ | |
| 5′-tcgctcagacctcactgcaatatc-3’ | 5′-tgtccaatggtgatggccagaatg-3’ | |
| 5′--gttcttcgttctcgtggctatcg3’ | 5′-atccacatcggaaactggctgag-3’ | |
| 5′-tcagttcgatttgtccacca-3’ | 5′-gatggcagcttgagtcaggt-3’ | |
| 5′-aagtacttgttcgccctcttcgc-3’ | 5′-acagggacccttgtatcttccg-3’ | |
| 5′-tcgcccttcaatcctaaccaacc-3’ | 5′-acgacatcagcagtgtgaatttcc-3’ | |
| 5′-ccgatgagctgaagtccaag-3’ | 5′-ttgccgttctccaccaccag-3’ | |
| 5′-tagcagtgccggatggaagaac-3’ | 5′-accctcataaagcggttgtgcag-3’ |